ONCOMATRYX vs Quince Therapeutics
ONCOMATRYX vs Quince Therapeutics, compared side by side on 19 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: ONCOMATRYX is on 50/100 and Quince Therapeutics on 37/100.
Where each one leads
ONCOMATRYX
- our overall score: 50/100 against 37/100
- funding raised: $107M against $63.0M
Quince Therapeutics
- domain rating: 38/100 against 26/100
At a glance
| Measure | ONCOMATRYX | Quince Therapeutics |
|---|---|---|
| What it is | Developing Quantum ADCs against the tumor microenvironment for innovative cancer therapies. | A biopharmaceutical company focused on developing novel therapies. |
| Category | Biotechnology, Pharmaceuticals, Healthcare, Biotech | Biotechnology, Pharmaceuticals, Healthcare |
| Sells toBusiness model | B2B | B2B |
| Offering | Services | Services |
| Founded | 2009 | 2020 |
| Headquarters | Derio, Spain | South San Francisco, USA |
| Status | Active | Active |
Size, funding and growth
| Measure | ONCOMATRYX | Quince Therapeutics |
|---|---|---|
| Employees | 36 | Not published |
| Total funding | $107M | $63.0M |
| Latest round | Funding Round | Series C |
| Valuation | Not published | $1.1B |
| LinkedIn followers | 5,170 | Not published |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | ONCOMATRYX | Quince Therapeutics |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 50/100 | 37/100 |
| Traction | 56/100 | 39/100 |
| Team | 30/100 | Not published |
| Search visibility | 37/100 | 13/100 |
| Quality | 55/100 | 45/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (36/100) | F (39/100) |
| Domain ratingLink authority, 0-100 | 26/100 | 38/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | ONCOMATRYX | Quince Therapeutics |
|---|---|---|
| Hosting | Self Managed | AWS |
| CMS | WordPress | WordPress |
| Frameworks | Jquery | Jquery |
| Analytics | Google Analytics 4 | Jetpack Stats |
ONCOMATRYX vs Quince Therapeutics: common questions
Which is better, ONCOMATRYX or Quince Therapeutics?
On our 0-100 score ONCOMATRYX rates higher (50/100 against 37/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 19 data points above: read the rows that match what you are buying for.
How do ONCOMATRYX and Quince Therapeutics compare on the numbers?
ONCOMATRYX leads on our overall score (50/100 against 37/100), funding raised ($107M against $63.0M). Quince Therapeutics leads on domain rating (38/100 against 26/100).
Read the full ONCOMATRYX review and pricing or the Quince Therapeutics review and pricing. You can also browse other ONCOMATRYX alternatives we track.